An observational study in Dermatitis, Atopic, sponsored by Pfizer. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Pfizer · Observational
The purpose of this observational study is to learn about the effects of the study medicine (called abrocitinib) for the treatment of severe atopic dermatitis in people that were moved from previous novel therapies, known as "advanced" therapies.
Atopic dermatitis is a long-lasting skin condition that causes the skin to become inflamed, dry, and itchy.
This study is seeking participants who:
All participants will receive study medicine, abrocitinib as part of their usual medical care. The decision to give the study medicine is made by their dermatologist. This decision is independent of participation in the study. Abrocitinib will be taken by mouth at home once daily as prescribed by the treating doctor.
We will examine the experiences of people receiving abrocitinib for up to one year after starting abrocitinib. We will look back at the information up to 6 months before they have started taking abrocitinib. This will help us learn how abrocitinib affects severe atopic dermatitis in people who have moved from other authorised advanced therapies.
Participants will take part in this study for 1 year. During this time, they will have about 5 visits. These visits are a part of their routine care. During the visits, the doctor will assess how severe atopic dermatitis is. Participants may be asked questions about their symptoms and how the condition affects their daily life.
No additional clinic visits, tests, or procedures are required for this study, beyond normal clinical practice.
1,443 studies on the registry are indexed under Dermatitis, Atopic; 253 are open to participants now.
This study's planned enrollment of 120 is below the median of 150 across 241 observational studies indexed under Dermatitis, Atopic.
Browse Dermatitis, Atopic studies →Pfizer is the lead sponsor of 3,323 studies on the registry; 145 are open to participants now.
Of its 597 completed or terminated interventional studies of FDA-regulated products, 391 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
severe atopic dermatitis adult (>=18 years) patients of both sexes who, according to clinical practice, have been switched directly to abrocitinib 100 mg or 200 mg after a maximum of 2 previous advanced therapies for the treatment of severe atopic dermatitis, including biologics (i.e., dupilumab, lebrikizumab, tralokinumab) and/or JAKis (i.e., baricitinib, upadacitinib).
Inclusion Criteria:
Adult patients with severe atopic dermatitis who switched from previous advanced therapies (dupilumab, lebrikizumab, tralokinumab, baricitinib, upadacitinib) to abrocitinib according to routine clinical practice
Drug: abrocitinib
Abrocitinib administered according to routine clinical practice at doses of 100 mg or 200 mg once daily.
Percentage of Participants Achieving Eczema Area and Severity Index (EASI) <7
Time frame: Week 24
EASI 90
Proportion of participants reaching 90% improvement in EASI from baseline
Time frame: Week 4, 12, 24, 52
Change from baseline in Eczema Area and Severity Index (EASI) Score
Time frame: Baseline, Week 4, 12, 24, 52
Change from baseline in Peak Pruritus-Numeric Rating Scale (PP-NRS) Score
Time frame: Baseline, Week 4, 12, 24, 52
Percentage of Participants Achieving PP-NRS <=1
Time frame: Week 4, 12, 24, 52
Change from baseline in Investigator's Global Assessment (IGA) Score
Time frame: Week 4, 12, 24, 52
Percentage of Participants Achieving IGA 0-1
Time frame: Week 4, 12, 24, 52
Change from baseline in Dermatology Life Quality Index (DLQI) Score
Time frame: Week 4, 12, 24, 52
Change From Baseline in Patient-Oriented Eczema Measure (POEM) Score
Time frame: Week 4, 12, 24, 52
Change from baseline in Sleep Disturbance Numeric Rating Scale (SD-NRS) Score
Time frame: Week 4, 12, 24, 52
Percentage of Participants Achieving Minimal Disease Activity (MDA)
Time frame: Week 4, 12, 24, 52
Demographics Characteristics: Percentage of Participants by Age, Gender, Education, Occupation, Family Status
Time frame: Baseline
Number of Participants by Age-at-Onset Category for Atopic Dermatitis
Age at onset
Time frame: Baseline
Number of Participants by Atopic Dermatitis Phenotype
Time frame: Baselines, Week 4, 12, 24, 52
Number of Participants with Each Difficult-to-Treat Body Area
Time frame: Baseline, Week 4, 12, 24, 52
Clinical Characteristics: Duration of Previous Advanced Therapy Before Switching to Abrocitinib
Time frame: Baseline
Number of participants with Each Atopic Comorbidity
Time frame: Baseline, Week 4,12,24,52
Number of Participants with Each Non-Atopic Comorbidity
Time frame: Baseline, Week 4,12,24,52
Adherence to Abrocitinib
Percentage of actual vs. expected therapeutic dosages as reported by the participants.
Time frame: Week 4,12, 24, 52
Persistence to Abrocitinib
Percentage of participants on treatment at week 52.
Time frame: Week 52
No study locations are listed for this record.
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.